NZ779331B2 - Method of improving sleep - Google Patents

Method of improving sleep

Info

Publication number
NZ779331B2
NZ779331B2 NZ779331A NZ77933120A NZ779331B2 NZ 779331 B2 NZ779331 B2 NZ 779331B2 NZ 779331 A NZ779331 A NZ 779331A NZ 77933120 A NZ77933120 A NZ 77933120A NZ 779331 B2 NZ779331 B2 NZ 779331B2
Authority
NZ
New Zealand
Prior art keywords
genotype
sleep
use according
disorder
cry1
Prior art date
Application number
NZ779331A
Other versions
NZ779331A (en
Inventor
Mihael Polymeropoulos
Sandra Smieszek
Original Assignee
Vanda Pharmaceuticals Inc
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Priority claimed from PCT/US2020/018082 external-priority patent/WO2020168056A1/en
Publication of NZ779331A publication Critical patent/NZ779331A/en
Publication of NZ779331B2 publication Critical patent/NZ779331B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

The invention provides methods of improving sleep using tasimelteon in a patient. Said patient having a variant of the cryptochrome circadian clock 1 (CRY 1) genotype or the period 1 (PER1) genotype which is associated with a circadian rhythm sleep disorder (CRSD), such as Delayed Sleep Wake Phase Disorder (DSWPD).

Claims (12)

1. The use of tasimelteon for the manufacture of a medicament for the treatment of a circadian rhythm sleep er (CRSD) or one or more symptoms associated with said disorder in a patient that has a cryptochrome circadian clock 1 (CRY1) genotype or period 1 (PER1) genotype associated with said disorder, wherein the genotype is selected from one of the group consisting of: CRY1 genotype associated with said disorder having at least one copy of the rs184039278 allele; CRY1 genotype associated with said disorder having at least one copy of the 14131 allele; and PER1 genotype associated with said er having at least one copy of the rs112474322 allele.
2. The use according to claim 1, wherein the CRY1 genotype associated with said disorder is a loss-of-function (LOF) genotype.
3. The use according to claim 1, wherein said disorder is delayed sleep wake phase disorder (DSWPD).
4. The use according to claim 1, wherein the medicament is formulated for administration of tasimelteon to the t once daily before bedtime.
5. The use according to claim 4, wherein the ment is formulated for administration of tasimelteon in a dose of 20 mg.
6. The use according to claim 1, wherein the one symptoms are ed from a group consisting of: latency to persistent sleep (LPS); sleep efficiency (%) during the first, second, and/or final thirds of the night; rapid eye movement (REM) sleep on; total sleep time (TST), including during the first two-thirds of the night; and wake after persistent sleep (WASO).
7. The use of tasimelteon for the manufacture of a ment for the improvement of one or more sleep parameters in an individual that possesses a variant of the cryptochrome ian clock 1 (CRY1) genotype or period 1 (PER1) genotype, wherein the genotype is selected from one of the group consisting of: CRY1 genotype with the rs184039278 allele; CRY1 genotype with the rs780614131 allele; and PER1 genotype with the rs112474322 allele.
8. The use according to claim 7, wherein the variant of the CRY1 or PER1 genotype is a f-function (LOF) genotype.
9. The use according to claim 7, wherein the sleep parameter is delayed sleep wake phase disorder (DSWPD).
10. The use according to claim 7, wherein the medicament is formulated for administration of tasimelteon to the patient once daily before bedtime.
11. The use according to claim 10, n the amount of lteon is 20 mg.
12. The use according to claim 7, wherein the one or more sleep ters are selected from a group consisting of: latency to persistent sleep (LPS); sleep efficiency (%) during the first, second, and/or final thirds of the night; rapid eye movement (REM) sleep duration; total sleep time (TST), including during the first two-thirds of the night; and wake after persistent sleep (WASO). FIG. ’I Arno; ,77777\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ \~‘.‘ ~\\\\v \ \\k gm“- In / /’2.,, 111/aIra/z
NZ779331A 2020-02-13 Method of improving sleep NZ779331B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962805057P 2019-02-13 2019-02-13
PCT/US2020/018082 WO2020168056A1 (en) 2019-02-13 2020-02-13 Method of improving sleep

Publications (2)

Publication Number Publication Date
NZ779331A NZ779331A (en) 2025-05-30
NZ779331B2 true NZ779331B2 (en) 2025-09-02

Family

ID=

Similar Documents

Publication Publication Date Title
JP4005115B1 (en) Pain disease treatment
US11458116B2 (en) Method of improving sleep
Rumende et al. The management of pulmonary fibrosis in COVID-19
CN100415240C (en) Use of p-benzaldehyde-O-β-D-alopyranoside in the preparation of medicines for treating neurogenic pain
NZ779331B2 (en) Method of improving sleep
CN108904516A (en) Application of the inosine in prevention and treatment depression
Zeng et al. IL-6 Inhibitor Tocilizumab Reduces Bone Resorption Around Implants with Bacterial Infection During Osseointegration: A Pilot Study in Rabbits.
WO2024092959A1 (en) Use of coclaurine and derivative thereof in improving nampt activity and pharmaceutical composition
CN101829132A (en) Application of 7-O-beta-D-acetylation sugar-coumarin compounds in treating chronic neuropathic pains
WO2024192227A1 (en) Tasimelteon for treating circadian rhythm sleep disorder
RU2021126438A (en) THE WAY TO IMPROVE SLEEP
Lee et al. Radiosurgery for vestibular schwannomas: preliminary results of the Adelaide experience
NZ783656B2 (en) Tasimelteon use in treating sleep aberrations
Rastogi et al. Role of L: methylfolate with Escitalopram from treatment initiation in depression
Kondyurova et al. Influence of Various Groups of Antibiotics on Socket Regeneration after Tooth Extraction: Review of Literature
Balaur et al. Ethical dilemmas of cyborgization in the context of scientific and technical progress
Huajin et al. Clinical study on the application of flapless technique in immediate implant restoration of anterior teeth
Lee et al. Wound Infiltration in Patients with Chronic Pain after Forehead Lift Surgery-A case report
Reddy Antibiotic prophylaxis in mandibular fractures treated with open reduction and internal fixation-a clinical study
Ryu Case report: treatment of facial nerve palsy following bilateral sagittal split ramus osteotomy
Que et al. Effects of lentivirus mediated shRNA targeting ILK on oral squamous cell carcinoma in vitro and in vivo
CN120114468A (en) Application of Ligustrum lucidum glycosides in the preparation of medicines for treating senile heart failure
Alimian et al. Comparing patient recovery after laparoscopic surgery for women using bispectral index and standard clinical method
Khan MD et al. A case of successful treatment of Skin Excoriation Disorder with N-Acetyl Cysteine
NZ783656A (en) Tasimelteon use in treating sleep aberrations